For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

BPC-157: origin, structure and research history

Research Library › Peptide Fragments

BPC-157 is a synthetic 15-amino-acid peptide (a pentadecapeptide) that corresponds to part of a larger protein, called Body Protection Compound (BPC), which Croatian researchers isolated from gastric juice. It was developed by Predrag Sikirić and colleagues at the University of Zagreb, with patents filed from 1989 and a first overview paper in 1993. As of 22 Oct 2026 it is not approved by the FDA or any other regulator.

Key facts

TypeSynthetic 15-amino-acid peptide (pentadecapeptide)
Derived fromBody Protection Compound (BPC), a protein of roughly 40,000 daltons isolated from gastric juice
Other namesBPC 157, PL 14736, Bepecin
First describedPatent priority 1989 (BPC); short peptides claimed 1992; overview paper 1993
Developed byPredrag Sikirić and colleagues, Department of Pharmacology, Medical School, University of Zagreb, Croatia
Designed targetNo receptor identified; FDA describes the substance as not well-characterized
Regulatory status (Oct 2026)Not FDA-approved; removed from FDA's Category 2 compounding list in April 2026; PCAC voted 8–6–1 in July 2026; no final FDA decision

Who developed it

BPC-157 came out of the Department of Pharmacology at the Medical School of the University of Zagreb, Croatia, where Predrag Sikirić led a long-running research group [1]. The team filed its first patents as individual inventors rather than through a company [2, 3].

The Croatian pharmaceutical company Pliva later took the peptide into development under the code PL 14736. Papers from the group in 2007 described it as being in trials with Pliva, but no full clinical trial report was ever published [4, 6].

What it was designed to target

The researchers first isolated a large protein, roughly 40,000 daltons in size, from human and animal gastric juice and named it Body Protection Compound, or BPC [2, 5]. A 1992 patent family then claimed a set of shorter peptides based on it. The best known of these is a 15-amino-acid sequence designated BPC 157 [3, 5].

Despite decades of preclinical publications, mostly in rats, no specific receptor for BPC-157 has been identified. In its 2026 briefing document, the FDA described the substance as not well-characterized [5, 6]. Any proposed mechanism therefore remains a hypothesis drawn from preclinical work.

Why it was created

The Zagreb group proposed that the stomach produces a substance that protects organs under stress, which they called the stomach-stress-organoprotection hypothesis. Their 1993 overview paper laid out this idea [7]. The original 1989 patent listed an unusually broad range of proposed applications, from the digestive tract to bone and beyond [2].

Pliva’s program was originally investigated in a research program on inflammatory bowel disease [4]. The FDA’s 2026 review located only a 2005 meeting abstract describing a small study in that area, plus a safety study in healthy volunteers registered in Mexico that posted no results [6].

Research timeline

  • 1989: Priority date of the first BPC patent application [2]
  • 1992: Patent family claims the short BPC peptides, including BPC 157 [3]
  • 1993: First overview paper on BPC and the organoprotection hypothesis [7]
  • 1994: US Patent 5,288,708 granted [2]
  • 2007: Papers describe BPC 157 as Pliva compound PL 14736 [4]
  • April 2026: FDA removes it from its Category 2 compounding list [8]
  • July 2026: FDA advisory committee votes 8–6, with one abstention [9, 10]

Regulatory status as of October 2026

BPC-157 is not approved as a drug by the FDA or by any other regulator. In April 2026 the FDA removed it, along with 11 other peptides, from its Category 2 list of bulk substances that raise significant safety concerns for compounding [8].

On 23–24 July 2026 the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8–6, with one abstention, to recommend adding BPC-157 to the list of substances pharmacies may compound, for a nominated use related to ulcerative colitis. The vote went against the recommendation of FDA staff [9, 10, 11]. The vote is advisory only; any list change requires rulemaking that could extend into 2027 [9]. As of 22 Oct 2026 the FDA had made no final decision.

On 14 Oct 2026 the FDA sent an interim access policy on compounding certain peptides to the White House for review; its text was not public [12]. BPC-157 is named under section S0 (non-approved substances) of the 2026 WADA Prohibited List [13].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who discovered BPC-157?

BPC-157 was developed by Predrag Sikirić and colleagues at the Department of Pharmacology, Medical School, University of Zagreb, Croatia, with patent filings beginning in 1989 [1, 2].

What does BPC stand for?

BPC stands for Body Protection Compound, the name the Zagreb team gave to a larger protein it isolated from gastric juice. BPC-157 is a 15-amino-acid peptide based on that protein [2, 5].

Is BPC-157 FDA approved?

No. As of 22 Oct 2026 BPC-157 is not FDA-approved. An FDA advisory committee voted in July 2026 on whether pharmacies may compound it, but the FDA has not issued a final decision, and compounding eligibility would not be an approval [9, 11].

Has BPC-157 been tested in controlled human trials?

The FDA’s 2026 review found no published full report of a controlled human trial, only a 2005 meeting abstract and an unpublished safety study [6].

Is BPC-157 on the WADA Prohibited List?

Yes. It is named under section S0, non-approved substances, on the 2026 WADA Prohibited List [13].

Sources

  1. Sever M, Klicek R, Radic B, et al., Sikiric P. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci. 2009;54:2070–2083. Link
  2. Sikiric P, Petek M, Rotkvic I, et al. Pharmacologically active substance BPC, the process for its preparation and its use in the therapy. US Patent 5,288,708; priority 12 Sep 1989, filed 11 Sep 1990, granted 22 Feb 1994. Link
  3. Sikiric P, Petek M, Seiwerth S, et al. BPC peptides, their preparation and use. EP 0572688 / WO 1993/024521 family (priority 30 May 1992); record KR0180256B1. Link
  4. Vuksic T, Zoricic I, Brcic L, et al., Sikiric P. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today. 2007;37:768–777. Link
  5. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185. doi:10.3390/ph18020185. Link
  6. U.S. FDA. Briefing document: BPC-157 (free base) and BPC-157 acetate, Pharmacy Compounding Advisory Committee, 23–24 Jul 2026 (dated 11 May 2026). Link
  7. Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313–327. doi:10.1016/0928-4257(93)90038-U. Link
  8. Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
  9. McDermott Will & Schulte. Bulk list bound: PCAC backs majority of peptides in two-day public meeting. 27 Jul 2026. Link
  10. Regulatory Focus (RAPS). FDA advisory committee backs two controversial peptides. 23 Jul 2026. Link
  11. Buchanan Ingersoll & Rooney. FDA advisory committee voted yes on six peptides. Now what? 18 Aug 2026. Link
  12. Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
  13. World Anti-Doping Agency. 2026 Prohibited List (S0 names BPC-157). Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top